1. Home
  2. VRTX vs SBUX Comparison

VRTX vs SBUX Comparison

Compare VRTX & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • SBUX
  • Stock Information
  • Founded
  • VRTX 1989
  • SBUX 1971
  • Country
  • VRTX United States
  • SBUX United States
  • Employees
  • VRTX N/A
  • SBUX N/A
  • Industry
  • VRTX EDP Services
  • SBUX Restaurants
  • Sector
  • VRTX Technology
  • SBUX Consumer Discretionary
  • Exchange
  • VRTX Nasdaq
  • SBUX Nasdaq
  • Market Cap
  • VRTX 96.6B
  • SBUX 89.2B
  • IPO Year
  • VRTX 1991
  • SBUX 1992
  • Fundamental
  • Price
  • VRTX $423.53
  • SBUX $86.34
  • Analyst Decision
  • VRTX Buy
  • SBUX Buy
  • Analyst Count
  • VRTX 26
  • SBUX 23
  • Target Price
  • VRTX $491.78
  • SBUX $98.52
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • SBUX 9.1M
  • Earning Date
  • VRTX 11-03-2025
  • SBUX 10-29-2025
  • Dividend Yield
  • VRTX N/A
  • SBUX 2.86%
  • EPS Growth
  • VRTX N/A
  • SBUX N/A
  • EPS
  • VRTX 14.07
  • SBUX 2.31
  • Revenue
  • VRTX $11,418,800,000.00
  • SBUX $36,689,300,000.00
  • Revenue This Year
  • VRTX $10.92
  • SBUX $4.28
  • Revenue Next Year
  • VRTX $9.55
  • SBUX $5.17
  • P/E Ratio
  • VRTX $30.04
  • SBUX $36.99
  • Revenue Growth
  • VRTX 10.46
  • SBUX 0.58
  • 52 Week Low
  • VRTX $362.50
  • SBUX $75.50
  • 52 Week High
  • VRTX $519.88
  • SBUX $117.46
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 61.96
  • SBUX 56.78
  • Support Level
  • VRTX $405.54
  • SBUX $83.65
  • Resistance Level
  • VRTX $432.76
  • SBUX $86.51
  • Average True Range (ATR)
  • VRTX 8.97
  • SBUX 1.71
  • MACD
  • VRTX 1.62
  • SBUX 0.64
  • Stochastic Oscillator
  • VRTX 71.05
  • SBUX 93.99

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About SBUX Starbucks Corporation

Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries at the end of March 2025. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.

Share on Social Networks: